All In Biotech

Drug Trial Radar · NCT00118430

Stepped Care for Depression and Musculoskeletal Pain

Stepped Care for Affective Disorders and Musculoskeletal Pain

Last checked: Nov 19, 2026Latest source record: May 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

500

Actual

Start

Sep 2004

Primary completion

Jul 2008

Study completion Aug 2008

Sponsor

Lead sponsor
Indiana UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Mental Health (NIMH)
First posted
Jul 11, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate the effectiveness of a stepped care approach in treating depression and reducing pain.

Conditions

  • Pain
  • Depression

Interventions

  • Stepped CareBehavioral

    Stepped care will consist of 12 weeks of antidepressant therapy, followed by a pain self-management program (PSMP) in those who fail to achieve both a good pain and global clinical response to antidepressant therapy. Treatment will be delivered by a nurse depression-pain clinical specialist (DPCS) who will be trained in providing both components of the stepped care treatment. The DPCS will meet weekly to review cases with a physician-investigator who will also be available to discuss any management issues that arise between the weekly case meetings. All participants will have six clinical contacts with the DPCS during the acute treatment phase and two clinical contacts during the continuation phase to assess medication adherence, adverse effects, and depression response.

  • AntidepressantsDrug

    Participants will be assigned to one of the following antidepressant regimens: venlafaxine (37.5 mg, increased to 75, 150, 225 mg); duloxetine (60 mg, increased to 120 mg); fluoxetine (20 mg, increased to 30 to 40 mg); sertraline (50 mg, increased to 100 to 150 mg); citalopram (20 mg, increased to 30 to 40 mg); paroxetine (20 mg, increased to 30 to 40 mg); or nortriptyline (25 mg, increased to 50 to 75 mg).

  • Usual CareDrug

    This group will receive care as usual from their providers and completes the same outcome assessments as the stepped care group.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Brief Pain Inventory InterferenceTime frame: Measured at Year 1
  2. HSCL-20 Depression SeverityTime frame: Measured at Year 1

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Indiana University Medical Center

    Indianapolis, Indiana

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.